Sudler & Hennessey appoints Co-CEOs

Share this article:

Sudler & Hennessey (S&H) has announced the appointment of co-CEOs – Rob Rogers and Louisa Holland – to head all operations in the Americas. The announcement was made in a statement on June 30. 

Rogers was the president of S&H's Asia Pacific operations from 2003 to 2006, before returning to the US as chief creative officer for North America. He will join Louisa Holland, previously the president of US operations, in the newly created co-CEO position.

“Rob and Louisa bring different skill sets which complement one another,” said Jed Beitler, chairman and worldwide CEO, adding that Rogers has international and promotional experience, while Holland is well versed in the domestic market and medical education, for example. “[The new appointments] increase our peripheral vision – the industry is no longer siloed in terms of disciplines, and the combined diversity and talent of Rob and Louisa insures that everything we do for our clients is in keeping with the evolving marketplace and changing world,” said Beitler.

Rogers and Holland are based out of S&H's New York City office. According to Beitler, the decision to establish co-CEOs reflects a philosophy of evolution at S&H, and a consolidation of geographical operations. “[Rogers and Holland]” are in charge of everything from the Hudson Bay down to Tierra del Fuego,” said Beitler. S&H is a subsidiary of Young & Rubicam, which was acquired by the London-based WPP Group in 2000.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.